Company / SG&A Expense
Oruka Therapeutics, Inc. SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$13.1M
FY2024
5-year range
$4.0M / $13.1M
FY2020-FY2024
Trend
+107.9%
vs FY2023
Sector context
#206 of 213
Health Care
What the data says
Among 213 Health Care companies, Oruka Therapeutics, Inc. is in the top 3% for sg&a expense. SG&A Expense has increased for 5 consecutive years, from $4M in FY2019 to $13M in FY2024.
Based on SEC 10-K filings.
$13M in FY2024 with a 5-year CAGR of +27.5%.
Increased from $6M to $13M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +39.9%
- 5-Year CAGR
- +27.5%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 213This company $13.1M Sector average $722.3M
▼
-98.2% below sector average
Key checks
Key Insights
- Oruka Therapeutics, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +27.5%, indicating consistent growth.
- In FY2024, sg&a expense increased 107.9% year-over-year.
- Ranks #206 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $13.1M | +107.9% |
| FY2023 | $6.3M | +14.2% |
| FY2022 | $5.5M | +15.3% |
| FY2021 | $4.8M | +19.9% |
| FY2020 | $4.0M | +2.6% |
| FY2019 | $3.9M | -16.3% |
| FY2018 | $4.6M | +8.7% |
| FY2017 | $4.3M | -2.9% |
| FY2016 | $4.4M | +8.0% |
| FY2015 | $4.1M | +1.4% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026